The following adverse reactions listed below have been accumulated from all clinical trials in patients treated with telmisartan for hypertension or in patients 50 years or older at high risk of cardiovascular events. Patients with primary aldosteronism generally will not respond to antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Red and white oblong shaped two layer tablet of 6.2 mm engraved with the company logo and the code 'H8'.MicardisPlus fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide and 80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.MicardisPlus should be taken in patients whose blood pressure is not adequately controlled by telmisartan alone. • Second and third trimesters of pregnancy (see sections 4.4 and 4.6).

Such conditions should be corrected before the administration of MicardisPlus. In functionally anephric patients the elimination half-life is about 34 hours. Serum insulin levels also tended to be lower in the Micardis group compared with the losartan group (P .09).3 Two independent investigator-led studies have suggested that the partial PPAR-gamma activation of Micardis may produce metabolic effects of potential clinical relevance, different from other ARBs. Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.In one study the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUCThe effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide. The absolute bioavailability of telmisartan at 40 mg and 160 mg was 42 % and 58 %, respectively. Exacerbation or activation of systemic lupus erythematosusRespiratory distress (including pneumonitis and pulmonary oedema)Abdominal pain, constipation, dyspepsia, vomiting, gastritisAngioedema (also with fatal outcome), erythema, pruritus, rash, hyperhidrosis, urticariaMuscoloskeletal, connective tissue and bone disordersGeneral disorders and administration site conditionsBlood creatinine increased, blood creatine phosphokinase increased, hepatic enzyme increased2: For further description, please see sub-section “Description of selected adverse reactions”Adverse reactions previously reported with one of the individual components may be potential adverse reactions with MicardisPlus, even if not observed in clinical trials with this product.Adverse reactions occurred with similar frequency in placebo and telmisartan treated patients. I take Micardis … Telmisartan (Micardis) is in the drug class of angiotensin receptor blockers (ARBs) and is prescribed for the treatment of high blood pressure, reducing the risk of heart attack, stroke, or death from cardiovascular causes (in patients aged 55 years and older). Call your doctor at once if you have: pale or yellowed skin, dark colored urine; Upper respiratory tract infection, urinary tract infection including cystitisMusculoskeletal, connective tissue and bone disordersGeneral disorders and administration site conditions3: For further description, please see sub-section “Description of selected adverse reactions”Hydrochlorothiazide may cause or exacerbate hypovolaemia which could lead to electrolyte imbalance (see section 4.4).Adverse reactions of unknown frequency reported with the use of hydrochlorothiazide alone include:Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma)Aplastic anaemia, haemolytic anaemia, bone marrow failure, leukopenia, neutropenia, agranulocytosis, Anorexia, appetite decreased, electrolyte imbalance, hypercholesterolaemia, hyperglycaemia, hypovolaemiaXanthopsia, acute myopia, acute angle-closure glaucoma, choroidal effusionLupus-like syndrome, photosensitivity reactions, skin vasculitis, toxic epidermal necrolysis, erythema multiformeMusculoskeletal, connective tissue and bone disordersNephritis interstitial, renal dysfunction, glycosuria General disorders and administration site conditionsMost cases of hepatic function abnormal / liver disorder from post-marketing experience with telmisartan occurred in Japanese patients. Hydrochlorothiazide is excreted in human milk in small amounts.